BRPI0814876A2 - Análogos de pirona fosforilados e métodos - Google Patents

Análogos de pirona fosforilados e métodos

Info

Publication number
BRPI0814876A2
BRPI0814876A2 BRPI0814876-7A2A BRPI0814876A BRPI0814876A2 BR PI0814876 A2 BRPI0814876 A2 BR PI0814876A2 BR PI0814876 A BRPI0814876 A BR PI0814876A BR PI0814876 A2 BRPI0814876 A2 BR PI0814876A2
Authority
BR
Brazil
Prior art keywords
pyrona
phosphorilated
analogs
methods
pyrona analogs
Prior art date
Application number
BRPI0814876-7A2A
Other languages
English (en)
Inventor
Wendye Robbins
Ving Lee
Original Assignee
Limerick Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Limerick Biopharma Inc filed Critical Limerick Biopharma Inc
Publication of BRPI0814876A2 publication Critical patent/BRPI0814876A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0814876-7A2A 2007-07-31 2008-07-30 Análogos de pirona fosforilados e métodos BRPI0814876A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95318807P 2007-07-31 2007-07-31
US7660808P 2008-06-27 2008-06-27
PCT/US2008/071588 WO2009018338A2 (en) 2007-07-31 2008-07-30 Phosphorylated pyrone analogs and methods

Publications (1)

Publication Number Publication Date
BRPI0814876A2 true BRPI0814876A2 (pt) 2014-09-30

Family

ID=40305253

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814876-7A2A BRPI0814876A2 (pt) 2007-07-31 2008-07-30 Análogos de pirona fosforilados e métodos

Country Status (13)

Country Link
US (3) US7947733B2 (pt)
EP (1) EP2182957A4 (pt)
JP (1) JP2011500512A (pt)
KR (1) KR20100051829A (pt)
CN (1) CN101969959A (pt)
AU (1) AU2008282261A1 (pt)
BR (1) BRPI0814876A2 (pt)
CA (1) CA2693338A1 (pt)
GB (1) GB2464645B (pt)
MX (1) MX2010001141A (pt)
TW (1) TW200924785A (pt)
WO (1) WO2009018338A2 (pt)
ZA (1) ZA201001390B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182957A4 (en) 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
EP2182801A4 (en) * 2007-07-31 2011-04-13 Limerick Biopharma Inc PYRONANALOGUE COMPOSITIONS AND CORRESPONDING METHODS
CN102438614A (zh) * 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
EP2424541A2 (en) * 2009-04-27 2012-03-07 Limerick BioPharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
EP2560652A4 (en) * 2010-04-23 2013-08-14 Kineta Inc ANTIVIRAL CONNECTIONS
WO2012068539A1 (en) * 2010-11-19 2012-05-24 Limerick Biopharma, Inc. Use and composition of quercetin-3'-o-sulfate for therapeutic treatment
WO2012154271A2 (en) 2011-02-25 2012-11-15 Kineta, Inc. Method and cells for identifying rig-i pathway regulators
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN104530127B (zh) * 2014-12-12 2016-09-14 广东东阳光药业有限公司 一种淫羊藿苷衍生物及其使用方法和用途
CN106632479B (zh) * 2016-12-22 2018-10-23 贵州大学 O,o’-二烷基-o”-(取代黄酮-3-基)磷酸酯类衍生物、制备方法及应用
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US10881634B2 (en) * 2017-12-07 2021-01-05 Hughes Biotechnology Co., Ltd Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR837588A (fr) 1938-03-25 1939-02-14 Perfectionnements aux chaînes ou garnitures anti-patinantes et anti-dérapantes pour roues de véhicules
US2764596A (en) * 1952-07-01 1956-09-25 Nat Drug Co Inorganic acid esters of polyhydroxylated flavones and flavanones
US4530844A (en) * 1984-07-26 1985-07-23 Warner-Lambert Company Synergistic non-steroidal anti-inflammatory compounds and compositions thereof
JPH01153695A (ja) * 1987-12-11 1989-06-15 Showa Denko Kk ルチンまたはケルセチンリン酸エステルの製造法
JPH01308476A (ja) 1988-06-06 1989-12-13 Showa Denko Kk 紫外線吸収剤
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
HUT66558A (en) 1991-11-18 1994-12-28 Merrell Dow Pharma Phosphorylated flavonoids in the treatment of viral diseases
JPH072826A (ja) 1992-03-12 1995-01-06 Sanwa Kagaku Kenkyusho Co Ltd フラボン誘導体
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US6362160B1 (en) * 1993-06-30 2002-03-26 The Johns Hopkins University School Of Medicine Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
WO1996021440A1 (en) 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
CA2306448A1 (en) * 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
NZ504711A (en) 1997-12-03 2002-02-01 Fujisawa Pharmaceutical Co Soft-pellet drug and process for the preparation thereof
JP2002503692A (ja) * 1998-02-23 2002-02-05 藤沢薬品工業株式会社 マクロライド系化合物の緑内障治療用途
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
JP2002509555A (ja) * 1998-04-06 2002-03-26 藤沢薬品工業株式会社 新規用途
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
AUPP584198A0 (en) * 1998-09-14 1998-10-08 Fujisawa Pharmaceutical Co., Ltd. New use
WO2000023102A1 (en) 1998-10-19 2000-04-27 New York University Method for regulating the permeability of the blood brain barrier
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
CA2358967A1 (en) 1999-01-27 2000-08-03 Zielinski Laboratory Hesperitin pro-forms with enhanced bioavailability
IL144828A0 (en) * 1999-03-11 2002-06-30 Fujisawa Pharmaceutical Co A pipecolic acid derivative containing liposome composition
PT1183261E (pt) 1999-05-25 2004-11-30 Fujisawa Pharmaceutical Co Metodo para separar compostos organicos analogos
AUPQ078799A0 (en) * 1999-06-04 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. New use
FI20000004A0 (fi) * 2000-01-03 2000-01-03 Slk Foundation Flavonoidilääke...
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
EP1299119A2 (en) * 2000-05-08 2003-04-09 David Haines Immunosuppressive compositions comprising an immunophilin-binding compound and a ginkgolide compound
FR2815033B1 (fr) * 2000-10-06 2003-09-05 Negma Lab Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique
DE10056400A1 (de) * 2000-11-14 2002-05-23 Merck Patent Gmbh Galenische Formulierung
US20040091477A1 (en) * 2001-05-08 2004-05-13 David Haines Immunosuppresive compositions
US20040102386A1 (en) * 2001-09-06 2004-05-27 Thomas Lahey Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto
CN1668287B (zh) * 2001-09-06 2012-03-28 赛诺克思公司 3-脱氧类黄酮在制备抑制t淋巴细胞活性的药物中的用途
GB0125532D0 (en) 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
US20060100179A1 (en) * 2002-08-14 2006-05-11 Pero Ronald W Compositions and methods for use in targeting vascular destruction
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
DE10240923A1 (de) 2002-09-02 2004-03-04 Merck Patent Gmbh Flavonoid-Derivate zur Ekzem-Behandlung
US20040209850A1 (en) * 2003-04-15 2004-10-21 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
KR20060067922A (ko) * 2003-06-10 2006-06-20 아스텔라스세이야쿠 가부시키가이샤 마크로라이드계 화합물을 함유하는 에어로졸 조성물이봉입용기에 봉입된 에어로졸 제제
JP2007509035A (ja) * 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
DE102004002787A1 (de) 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe
US7875650B2 (en) * 2004-02-03 2011-01-25 Yale University Compounds and methods to increase anti-P-glycoprotein activity of baicalein by alkylation on the A ring
CN1297552C (zh) 2004-03-11 2007-01-31 南京莱尔生物化工有限公司 木犀草素的合成方法
AU2005263551B2 (en) 2004-07-16 2009-04-09 Novartis Ag Use of a steroid for enhancement of skin permeability
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
CA2579784C (en) * 2004-09-14 2013-02-26 Ajinomoto Omnichem S.A. Topical compositions containing phosphorylated polyphenols
US20060069042A1 (en) * 2004-09-24 2006-03-30 Hu Oliver Y Cytochrome P450 2C9 inhibitors
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US20070087977A1 (en) 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
EP1817023A4 (en) * 2004-11-16 2010-08-18 Limerick Biopharma Inc METHODS AND COMPOSITIONS FOR TREATING PAIN
AU2006222556B2 (en) 2005-03-11 2011-09-29 Armaron Bio Pty Ltd Flavonoid compounds and uses thereof
US20080242599A1 (en) 2005-05-03 2008-10-02 Majd Zayzafoon Compositions and Methods for Increasing Osteoblast Cell Differentiation and Bone Generation
WO2007016525A2 (en) * 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007084857A2 (en) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
CA2645633A1 (en) 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
GB0618168D0 (en) 2006-09-15 2006-10-25 Babraham Inst Compounds
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
MX2009006958A (es) 2006-12-28 2009-07-09 Limerick Biopharma Inc Metodos y composiciones para tratamiento terapeutico.
WO2009018326A2 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
EP2182801A4 (en) * 2007-07-31 2011-04-13 Limerick Biopharma Inc PYRONANALOGUE COMPOSITIONS AND CORRESPONDING METHODS
EP2182957A4 (en) 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
WO2009158007A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
CN102438614A (zh) 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
US20100297020A1 (en) * 2008-10-10 2010-11-25 Limerick Biopharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
EP2424541A2 (en) 2009-04-27 2012-03-07 Limerick BioPharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment

Also Published As

Publication number Publication date
EP2182957A4 (en) 2012-07-18
MX2010001141A (es) 2010-03-01
US20090069273A1 (en) 2009-03-12
US20100204089A1 (en) 2010-08-12
US7947733B2 (en) 2011-05-24
GB2464645B (en) 2010-11-24
TW200924785A (en) 2009-06-16
KR20100051829A (ko) 2010-05-18
AU2008282261A1 (en) 2009-02-05
CA2693338A1 (en) 2009-02-05
CN101969959A (zh) 2011-02-09
GB201002044D0 (en) 2010-03-24
ZA201001390B (en) 2011-05-25
US20100144612A1 (en) 2010-06-10
EP2182957A2 (en) 2010-05-12
GB2464645A (en) 2010-04-28
WO2009018338A2 (en) 2009-02-05
JP2011500512A (ja) 2011-01-06
WO2009018338A3 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DE502007001207D1 (de) Elektrosaugkopf
DK2159224T3 (da) Bromphenylsubstituerede thiazolyldihydropyrimidiner
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE602008002772D1 (de) Polyvinylpyrrolidonpulverzusammensetzungen
DE112008003636A5 (de) Mehrzuggruppierer
BRPI0811451A2 (pt) Exopolissacarídeo
DE602008000923D1 (de) Einzelwaferätzgerät
DE602008000749D1 (de) Buschschneider
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812840A2 (pt) 2-imidazolinas
AT505058A3 (de) Türschliesssystem
DE602008001234D1 (de) Bandmaterialzuführvorrichtung
BRPI0812994A2 (pt) Microbiocidas
DE602008004695D1 (de) Katalysatorträgerwabe
BRPI0809678A2 (pt) Métodos
DE602008005589D1 (de) Rliganden
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
DE112008003196A5 (de) Handpipettiergerät
DE602008000292D1 (de) Werkzeughaltepositioniervorrichtung

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]